FHA Domain Recombinant Protein for Antibody-Like Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing antibodies are costly, time-consuming, and lack specificity and consistency in protein purification and characterization, particularly due to the inefficiencies in expression systems like E. coli and the immunogenicity of animal-derived antibodies.
Innovation Solution
A recombinant protein with an antibody-like scaffold, specifically the FHA domain, is modified to generate a library of variants with altered amino acid sequences for high-throughput screening of antigen binding, capable of being used in protein isolation and characterization methods, including therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antibody production methods (animal immunization) are used, then specific binding antibodies can be obtained, but the production process is costly and time-consuming
Solution Approach 1:
The patent creates a recombinant protein that copies the essential binding function of antibodies using a simplified scaffold structure (FHA domain). Instead of producing full antibodies through complex animal immunization, the invention synthesizes a smaller protein model that replicates the antigen-binding capability, thereby reducing production time and cost while maintaining specific binding reliability
Solution Approach 2:
The patent modifies the FHA domain protein by changing amino acid sequences in loop regions to alter binding specificity. By systematically varying parameters such as loop length, composition, and structure, the invention generates a library of variants with different binding properties, enabling rapid screening and selection of high-affinity binders without traditional immunization processes
2Productivity
If recombinant antibodies are expressed in E. coli, then production cost and time are reduced, but expression yields are suboptimal
Solution Approach 1:
The patent employs a simplified protein scaffold (FHA domain) that is easier and cheaper to produce in E. coli compared to full antibodies. The smaller size and simpler structure of the FHA domain allow for efficient bacterial expression, sacrificing some of the complexity of natural antibodies but gaining substantial improvements in production efficiency and yield
Solution Approach 2:
The patent divides the antibody function into essential and non-essential components, retaining only the antigen-binding capability through the FHA domain scaffold. By segmenting the protein structure and removing unnecessary regions (such as Fc regions and extensive constant domains), the invention creates a minimal functional unit that expresses efficiently in E. coli while maintaining binding activity
3Reliability
If animal-derived antibodies are used, then specific binding is achieved, but immunogenicity problems occur in therapeutic applications
Solution Approach 1:
The patent creates a human-compatible protein model (FHA domain) that copies the binding function of antibodies without using animal-derived components. This synthetic scaffold approach produces a therapeutic agent that is less immunogenic than traditional animal antibodies while maintaining specific binding capability, thereby eliminating the harmful immunogenicity effect
4Manufacturing precision
If protein purification methods are improved, then specificity and efficiency increase, but complexity of the process increases
Solution Approach 1:
The patent extracts and utilizes the FHA domain's natural affinity for phosphothreonine residues to simplify purification. By leveraging this inherent binding property, the invention enables straightforward affinity chromatography using phosphopeptide ligands, eliminating the need for complex multi-step purification protocols while achieving high specificity and efficiency
Data Source
Figure 1(i)~1(ii)
Figure 2
Figure 3
AI summary
A general method and recombinant nucleic acid sequences, by means which the method selects a recombinant protein containing an FHA domain for binding a target molecule from a library proteins with a high-throughput method of creating protein variations within the FHA domain in non-conserved or non-structural sequences of the FHA scaffold, and the library may also be in the form of a phagemid or phage library wherein the ALP nucleic acid sequence is inserted into a vector capable of allowing the vector and expressed ALP protein from being virally packaged, and the recombinant nucleic acid sequences which are randomly mutated at varying non-conserved or non-structural FHA domain sequences.